Gene expression profiling in MDS and AML: potential and future avenues.
about
Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and MaintenanceCombining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.Machine-learned cluster identification in high-dimensional data.Identification of expression patterns in the progression of disease stages by integration of transcriptomic data.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Leukemia gene atlas--a public platform for integrative exploration of genome-wide molecular data.Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblastsUsing bioinformatic approaches to identify pathways targeted by human leukemogensApoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic LeukemiaGEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays.The myelodysplastic syndrome as a prototypical epigenetic diseaseMultidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.Epigenetics of myelodysplastic syndromes.High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factorSecondary myeloid neoplasias: an emerging group of diseases.New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients.Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions.Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.An acquired defect associated with abnormal signaling of the platelet collagen receptor glycoprotein VI.Surface plasmon resonance biosensor for the detection of VEGFR-1--a protein marker of myelodysplastic syndromes.Bone Marrow Defects and Platelet Function: A Focus on MDS and CLL.Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patientsCellular origin of prognostic chromosomal aberrations in AML patients
P2860
Q28072920-1876D431-17F9-409F-A167-24B9FF920007Q30883788-EEF7A832-284C-4C08-95C1-06288BE2D35BQ31152226-E6D203C9-D417-465A-B812-4D707BD4815CQ31160928-000CD645-E5AD-4755-B54D-AB8B9F75D1D5Q34260622-64B24EE9-EC65-4EBB-AC59-AE3F9280C7B7Q34312209-91644FBB-4AF6-40AF-9E80-7C4B6ADF1F0BQ35625385-B983A198-A977-49B8-AAEA-5C1B11848202Q36126146-4653A680-9C95-44D1-A69D-89BDECB0FA97Q36208342-F3777EEA-67D0-4317-82F0-B863FA754954Q36216225-349049A9-A53B-446D-917F-BE32FF8175E9Q36322508-5EA3C239-43FD-43EA-9034-6D8955F915E2Q36507980-9B89143F-B21A-4D42-A242-3A5000B9BA0BQ36678141-A1EEF7E1-9765-4B5A-A8F7-23827E849A10Q36720677-F52B9714-4A69-4704-8574-E6BB858EBEE3Q36833557-09A471CC-2F19-4F70-B6FE-1800797B2F2EQ37076249-9D83AE89-ADC1-48E8-809A-1523D049CAC6Q38113583-1BE2F434-FE16-4975-806A-F1AFF751BC94Q38163846-39D9E828-8733-4D00-89F5-A01F8648E244Q38301831-FF717665-02E1-43B4-B9B5-F23D950F0CA9Q42127316-6AB7D3B9-0E9F-42B5-B760-5F237C57553BQ42587954-19DB6A7A-2D54-46FE-8CB1-6A2C8718DFBEQ43880033-119A6D3C-AFE2-4A46-ACE1-3DA08B052405Q44097865-831BB598-5AA2-4260-8739-C34C894490E8Q47137221-55DE082E-2F92-4182-B7F8-5F1D3D39846EQ47569368-C725EA40-9EB1-4E20-9491-EED07EDD4166Q54362642-1A374261-0499-4640-B038-E8664E47615AQ54488259-26F6A44D-71DD-4894-93EC-861B42C569ADQ54558737-DF6B3427-E9BE-4128-BD81-8A6DDA4FEF81Q55452542-C1557ABF-1112-4BB9-A467-88B4C94B1FBFQ56974946-292D6897-1AFF-4F2E-B089-78D7EA477404Q57384752-383A66BF-B0C7-425C-9ACF-C4F506F0FD43
P2860
Gene expression profiling in MDS and AML: potential and future avenues.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Gene expression profiling in MDS and AML: potential and future avenues.
@en
Gene expression profiling in MDS and AML: potential and future avenues.
@nl
type
label
Gene expression profiling in MDS and AML: potential and future avenues.
@en
Gene expression profiling in MDS and AML: potential and future avenues.
@nl
prefLabel
Gene expression profiling in MDS and AML: potential and future avenues.
@en
Gene expression profiling in MDS and AML: potential and future avenues.
@nl
P2093
P2860
P50
P356
P1433
P1476
Gene expression profiling in MDS and AML: potential and future avenues
@en
P2093
A Kohlmann
J Wainscoat
L Bullinger
M M Van den Heuvel-Eibrink
P2860
P2888
P304
P356
10.1038/LEU.2011.48
P50
P577
2011-03-29T00:00:00Z